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Background: The purpose of this study was to analyze the efficacy and tolerability of palliative radiotherapy (RT) in
patients with a poor performance status (PS) and to evaluate the relationship between the palliative effect and
survival time.
Methods: One hundred and thirty-three patients with a poor PS (Eastern Cooperative Oncology Group 3 or 4) were
treated with palliative RT using the three-dimensional conformal technique and retrospectively analyzed. Each
patient's primary symptom treated with palliative RT as the major cause of the poor PS was evaluated using the
second item of the Support Team Assessment Schedule (STAS) at the start and one week after the completion of
palliative RT.
Results: One hundred and fourteen (86%) of the 133 patients completed the planned palliative radiation dose.
Grade 3 acute toxicity was observed in two patients (2%) and Grade 2 acute toxicity was observed in 10 patients
(9%). No Grade 2 or higher late toxicities were observed, except for Grade 3 radiation pneumonitis in one patient.
Improvement in the STAS scores between pre- and post-palliative RT was recorded in 76 (61%) of the 125 patients
with available scores of STAS. A significant improvement in the mean STAS score between pre- and post-palliative
RT was recognized (p < 0.0001). Improvement in the STAS score was found to be the most statistically significant
prognostic factor for overall survival after palliative RT in both the multivariate and univariate analyses. The median
overall survival time in the patients with an improvement in the STAS score was 6.4 months, while that in the
patients without improvement was 2.4 months (p < 0.0005).
Conclusions: Palliative RT in patients with a poor PS provides symptomatic benefits in more than half of patients
without inducing severe toxicities. The palliative effect is strongly correlated with prolongation of the survival time
and may contribute to improving the remaining survival time in patients with metastatic/advanced cancer with a
poor PS.
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Radiation therapy (RT) is widely used to treat cancer,
which has become a leading cause of death in Japan,
with 275,000 Japanese patients dying of cancer in 2010.
RT with palliative intent is administered in approxi-
mately 35-50% of cancer patients [1]. Distressing symp-
toms, including pain, bleeding and obstruction, can
often be relieved with minimal toxic effects [2]. Painful
bone metastasis, in particular, is common in oncologic
practice.
The performance status (PS) has been demonstrated
to be strongly correlated with survival as well as treat-
ment outcomes in all types of cancer patients [3]. This
may explain why a poor PS is negatively correlated with
the RT referral rates [4]. Potential risks, such as serious
acute side effects, discomfort associated with the waiting
time for treatment, transportation, hospitalization and
the duration of the RT course, are concerns in patients
with a poor PS [5,6]. Few clinical studies have assessed
the effects of palliative RT in patients with a poor PS,
and the merit and prognostic factors of palliative RT
have not been established [7,8].
Several previous studies have demonstrated that the
baseline QoL is a significant predictor of survival in pa-
tients with advanced cancer [9-11]. Improvements in
the QoL in addition to palliative effects have also been
recognized following the administration of palliative RT
in several studies [12,13]. The use of palliative RT,
especially that administered to treat bone metastasis,
should be considered due to its valuable effects, even in
patients with an estimated survival time of three
months [14]. Several surgical interventions performed
with a palliative intent have exhibited survival benefits
in advanced cancer patients with a poor PS [15,16].
Poststenting RT effectively prolonged the duration of
dysphagia relief and improved the overall survival in
patients with inoperable esophageal cancer in a ran-
domized trial [17]. In this context, we hypothesized that
a meaningful effect of palliative RT would result in pro-
longation of the limited survival time in patients with
advanced/metastatic cancer with a poor PS.
The Support Team Assessment Schedule (STAS) is a
proxy assessment scale used to evaluate palliative care
that was originally developed in the UK and is cur-
rently used worldwide [18-20]. The second item of the
STAS, symptom control, evaluates the patient’s most
severe symptom. The reliability of assessing the pri-
mary symptom using the second item of the STAS has
been previously established [21]. The purpose of this
study was to evaluate the palliative effect, assessed
based on the second item of the STAS, and tolerability
of palliative RT in patients with a poor PS and to
analyze the relationship between the palliative effect
and the survival time.Methods
Patients
Between May 2006 and May 2012, 350 consecutive pa-
tients were treated with palliative RT at the authors’
institution. During the same period, there were 133 con-
secutive patients with 150 lesions treated with palliative
RT with a poor PS (Eastern Cooperative Oncology Group
3 or 4) at the start of palliative RT; these patients were
enrolled in this retrospective study. Table 1 shows the
patients’ clinical characteristics. The pretreatment evalu-
ation included a complete history, physical examination,
complete blood count, body computed tomography scan
and, in some cases, 18 F-FDG PET/CT and/or magnetic
resonance imaging and/or bone scintigraphy. Concomi-
tant diseases associated with a worse performance status
were recognized in 19 patients as follows: dementia
(n = 8), cerebrovascular disease (n = 5) and others (n = 6).
This study was approved by the Institutional Review
Board of the authors’ institution.
Palliative radiotherapy
All patients were treated with external RT using a linear
accelerator with 4, 10 MV or 5–15 MeV electrons (Toshiba
PRIMUS linear accelerator equipped with standard multi-
leaf collimators). Computed tomography (CT) images were
obtained in 5-mm increments over the region of interest.
Three-dimensional conformal RT was performed using the
Xio (CMS Japan, Tokyo, Japan) treatment planning system
in all patients. The clinical target volume (CTV) was de-
fined as the primary tumor or metastatic site (gross tumor
volume) plus a 0.5-1.0-cm margin. The planned target
volume (PTV) was defined as the CTV plus 0.5-1.0 cm for
the daily setup variation and respiratory movement. To re-
duce the irradiation dose to the organs at risk, 34 (23%) of
the 150 lesions were treated with a three- or four-field
beam arrangement or conformational therapy. The sched-
ule of palliative RT was as follows: 30 Gy in 10 fractions in
95 lesions (63%), 20 Gy in five fractions in seven lesions
(5%), 39 Gy in 13 fractions in five lesions (3%), 8 Gy in one
fraction in two lesions (1%) and other in 41 lesions (27%).
STAS measurements
Each patient's primary symptom treated with palliative
RT as the major cause of the poor PS was evaluated
using the second item of the STAS (Japanese version) at
the start of and one week after the completion of pallia-
tive RT by one of four radiation oncologists. The second
item of the STAS, the various symptom control item, was
rated on a 5-point Likert scale with the following defini-
tions: 0 = none, 1 = occasional, single or few symptom(s),
the patient performs usual activities and is not bothered
by the symptom(s), 2 =moderate distress, occasional bad
days, the symptoms limit some activities depending on the
extent of the disease, 3 = severe symptom(s) present often,
Table 1 Patient clinical characteristics
Variable n (%)
Age (y)




















No. of metastatic lesion
0-3 30 (23)
≧ 4 103 (77)
Histology
Squamous cell carcinoma 30 (23)
Adenocarcinoma 35 (26)
Small cell carcinoma 15 (11)
Hepatocellular carcinoma 6 (5)
Transitional cell carcinoma 6 (5)
Other 41 (31)
No. of irradiated site
One site 117 (88)
Two sites 15 (11)
Three sites 1 (1)


















Head and neck 3 (2)
Others 4 (3)
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the symptom(s), 4 = severe and continuous overwhelm-
ing symptom(s), the patient is unable to think of other
matters.
Evaluation of the tumor response, progression criteria
and toxicity
The tumor response was evaluated according to the Re-
sponse Evaluation Criteria in Solid Tumors using CT
and/or a physical examination [22]. The absence of local
progression was defined as locally controlled disease,
and local control was analyzed in patients monitored for
a minimum follow-up of one month. The overall sur-
vival was calculated from the first day of palliative RT to
the date of death.
Toxicity was graded using the National Cancer Insti-
tute Common Toxicity Criteria (CTCAE) version 3. The
highest toxicity grade for each patient was used for the
toxicity analysis. The toxicity was defined as acute (oc-
curring during therapy and up to three months after
therapy) or late (over three months after the completion
of therapy).
Statistical analysis
The Wilcoxon signed-rank test was used to assess the
STAS scores between pre- and postpalliative RT. Univar-
iate analyses using Fisher’s exact test and multivariate
analyses using logistic regression were performed to
evaluate the effects of certain factors on improvement of
the STAS score. The overall survival and local control
rates were calculated using the Kaplan–Meier method.
The statistical significance of the differences between the
actuarial curves was assessed using the log-rank test. To
identify prognostic factors for overall survival, univariate
analyses were performed using gender, age, PS, concomi-
tant disease, number of tumors, irradiated site, total RT
dose, completion of the planned RT dose, chemotherapy,
primary tumor site, target of palliative RT and improve-
ment in the STAS score. Multivariate analyses using the
Cox proportional–hazards model were performed to
Table 2 Univariate and multivariate analyses to evaluate
effects of certain factors on an improvement of STAS




M/F 76/49 0.85 -
Age
< 70/≧ 70 47/78 0.56 -
Performance status
3/4 98/27 0.074 0.013
Concomitant disease
Yes/No 14/111 0.078 0.322
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PS, concomitant disease, number of tumors, total RT
dose, completion of the planned RT dose, primary tumor
site and improvement in the STAS score.
Results
The median follow-up period was 2.3 months (range 0.0–
47.4) in all patients. One hundred and fourteen (86%) of
the 133 patients completed the planned palliative RT dose.
The remaining 19 patients (14%) were unable to complete
the planned dose due to the following reasons: worsening
of the patient’s general condition/comorbidities in 14 pa-
tients, patient refusal to continue palliative RT in four
patients and acute radiation proctitis in one patient. Re-
garding acute toxicities, Grade 3 complications were
observed in two patients (appetite loss and proctitis) and
Grade 2 complications were observed in 10 patients
(esophagitis in six patients, appetite loss in two patients,
oral mucositis in one patient and tinnitus in one patient).
With respect to late toxicities, there were no Grade 2 or
higher complications, except for Grade 3 radiation pneu-
monitis in one patient with lung cancer.
The STAS scores of eight (6%) of the 133 patients
were not evaluated due to dementia caused by brain me-
tastases in five patients and deterioration of conscious-
ness in three patients. Improvements in the STAS scores
between pre- and postpalliative RT were recorded in 76
(61%) of the total 125 patients, 35 (64%) of the 54 patients
with pain, nine (64%) of the 14 patients with dyspnea, six
(46%) of the 13 patients with symptoms of increased
intracranial pressure, three (30%) of the 10 patients with
paralysis and four (44%) of the nine patients with bleeding.
The mean STAS scores of all patients at pre- and
postpalliative RT were 3.3 and 2.3, respectively, with a sta-
tistically significant difference (p < 0.0001) (Figure 1). The
mean STAS scores at pre- and postpalliative RT were 3.6
and 2.2 (p < 0.0001) in the 54 patients with pain, 3.6 andFigure 1 Mean STAS scores pre- and postpalliative
radiotherapy. ICP: increased intracranial pressure.2.6 (p = 0.005) in the 14 patients with dyspnea, 3.2 and 2.8
(p = 0.03) in the 13 patients with symptoms of increased
intracranial pressure, 3.7 and 3.0 (p = 0.09) in the 10 pa-
tients with paralysis and 2.0 and 1.4 (p = 0.05) in the nine
patients with bleeding, respectively (Figure 1). Table 2
shows the results of the univariate and multivariate ana-
lyses performed to evaluate the effects of certain factors
on improvements in the STAS scores among the 125 pa-
tients with available STAS scores. According to the uni-
variate analyses, the irradiated site of bone, completion of
the planned RT dose and a total RT dose of ≧30 Gy were
found to be significant factors. According to the multivari-
ate analyses, the irradiated site of bone and a performance
grade of 3 were found to be significant factors.
The median overall survival time of all patients was
4.5 months. The overall survival rate at one year in all
patients was 31%. The 1-year local control rate for the
93 patients who were monitored for a minimum follow-
up of one month was 72%. In the univariate analyses of
the 125 patients with available STAS scores, the statisti-
cally significant factors for better overall survival ratesNo. of tumor lesion
1-3/≧ 4 25/100 0.36 -
Irradiated site
Bone/others 71/54 0.0054 0.0074
Target of palliative RT
Metastatic/primary 97/28 0.20 -
Primary tumor site
Lung/others 51/74 0.58 -
Total RT dose (Gy)
< 30/≧ 30 20/105 0.047 0.78
Completion of planned RT dose
Yes/No 109/16 0.013 0.16
Chemotherapy
Yes/No 25/100 0.82 -
RT radiotherapy.
Table 3 Results of the univariate and multivariate
analyses of certain factors for overall survival rates after
palliative RT in125 patients with available scores of STAS
Univariate Multivariate
MST OR
n (mos) p (95% CI) p
Gender
M 76 4.5 0.20 - -
F 49 6.3
Age
< 70 47 5.6 0.65 - -
≧ 70 78 4.1
Performance status
3 98 6.3 0.026 1.9 0.064
4 27 2.0 (1.0-3.9)
Concomitant disease*
Yes 14 26.8 0.011 4.5 0.0084
No 111 3.8 (1.5-13.7)
No. of tumor lesion
1-3 25 6.3 0.041 1.4 0.42
≧ 4 100 3.6 (0.6-3.1)
Irradiated site
Bone 71 4.7 0.94 - -
Others 54 4.4
Target of palliative RT
Metastatic tumor 97 3.8 0.14 - -
Primary tumor 28 6.3
Primary tumor site
Lung 51 3.4 0.020 2.2 0.011
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presence of concomitant diseases, completion of the
planned RT dose, a non-lung primary tumor site, a per-
formance status of 3 and the presence of one to three
tumors (Figure 2). The median overall survival time in
the patients with an improvement in the STAS score
was 6.4 months, while that of the patients without an
improvement of the STAS score was 2.4 months
(p = 0.0005) (Figure 2). In the multivariate analyses of
the 125 patients, an improvement in the STAS score, the
presence of concomitant diseases, a PS of 3 and a non-
lung primary tumor site were found to be statistically
significant prognostic factors (Table 3). An improvement
in the STAS score was the most statistically significant
prognostic factor for overall survival following palliative
RT in both the multivariate and univariate analyses.
Discussion
The present study is the first study to assess the various
palliative RT effects observed in patients with a poor PS
using the second item of the STAS. To our knowledge,
previous reports of detailed treatment results of pallia-
tive RT in patients with a poor PS are limited [7,8].
Yamazaki et al. analyzed the feasibility of palliative RT in
patients with an ECOG PS of 3–4 and found that the
treatment completion rate (79%) in the patients with a
PS of 3–4 was significantly worse than that (89%) ob-
served in the patients with a PS of 0–2 [8]. Campos
et al. demonstrated that the PS, as measured by KPS, is
significantly related to the response rate one month after
palliative RT in patients with painful bone metastases. In
their study, the response rate was 44% in patients with a
KPS of ≦40, 44% in patients with a KPS of 50–60, 57%Figure 2 An improvement in the STAS score between pre- and
postpalliative RT was found to be a statistically significant
prognostic factor for overall survival after palliative RT
(p = 0.0005).
Others 74 6.1 (1.2-3.9)
Total RT dose (Gy)
<30 20 0.7 0.080 1.1 0.91
≧ 30 105 4.9 (0.4-2.7)
Completion of planned RT dose
Yes 109 5.0 0.0025 2.0 0.170
No 16 0.5 (0.7-5.2)
Chemotherapy
Yes 25 5.6 0.82 - -
No 100 3.9
Improvement of STAS score
Yes 76 6.4 0.0005 3.7 <0.0001
No 49 2.4 (2.0-6.6)
RT radiotherapy, STAS Support Team Assesment Schedule, MST median
survival time, OR odds ratio, CI confidence interval.
*associated with a worse performance status.
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with a KPS of 90–100; however, no such relationships
were observed at two or three months [7]. Dennis et al.
reported that patients suffering from painful bone me-
tastases with an estimated survival of three months
whose median KPS score is 60 should still be considered
for palliative RT because, in their study, the overall rate
of pain relief was as favorable as 70% at one month and
63% at two months [14]. Similarly, in the current study,
the treatment completion rate was 86%, and an improve-
ment in the STAS score following palliative RT was
recorded in 64% of the patients with pain. In addition, a
PS of 3 was found to be a better predictive factor of im-
provements in the STAS score than a PS of 4 in the
multivariate analyses. We confirmed that administering
palliative RT in patients with a poor PS is feasible and
offers significant palliative effects, especially in patients
with pain, dyspnea and symptoms of increased intracra-
nial pressure.
Previous studies have shown that the baseline QoL is
a strong independent predictor of survival in patients
with advanced cancer [9-11]. Langendijk et al. reported
that the global QoL assessed using the EORTC QLQ-
C30 is also a strong prognostic factor for survival in
patients with NSCLC treated with RT [23]. There are
few reports regarding the correlation between the pal-
liative effects of RT and the duration of survival [24].
Stevens et al. reported that, according to a multivariate
analysis, the independent predictive factors for overall
survival in head and neck cancer patients treated with
palliative RT included a positive treatment response
and a higher radiation dose [24]. Recently, Temel et al.
examined the effects of introducing palliative care early
after diagnosis in a randomized trial of patients with
metastatic non-small cell lung cancer and demon-
strated that providing early palliative care led to signifi-
cant improvements in both the quality of life and
duration of survival [25]. Nieder et al. demonstrated
that, in a randomized clinical trial of whole-brain RT
versus best supportive care in patients with brain me-
tastases and adverse prognostic factors, significant im-
provements in survival time were observed in the
30 Gy whole-brain RT group in comparison to the
20 Gy whole-brain RT group [26]. In the current study,
an improvement in the STAS score following palliative
RT was found to be the most statistically significant
prognostic factor for overall survival in both the uni-
variate and multivariate analyses. Therefore, we sup-
pose that the good palliative effects of RT observed in
patients with a poor PS can result in not only improve-
ment of the QoL, but also prolongation of the limited
survival time.
Chow et al. reported a predictive model for survival
from the time of presentation in an outpatient palliativeRT clinic and found that six prognostic factors (primary
cancer site, site of metastases, Karnofsky PS and the
fatigue, appetite and shortness-of-breath items on the
Edmonton Symptom Assessment Scale) had a statisti-
cally significant impact in the 395 patients who were
prospectively analyzed [27]. In the current study, the
palliative effect at one week after the completion of RT
was found to be the most statistically significant prog-
nostic factor for overall survival, although the primary
cancer site and PS were also identified as significant pre-
dictors. Therefore, the palliative RT effect, as well as
previously reported prognostic factors, may contribute
to predicting the survival time in metastatic/advanced
cancer patients with a poor PS.
The proxy assessment of the STAS scale has been used
in various palliative settings, including support teams in
the community, hospitals and hospices and in both can-
cer and acquired immunodeficiency syndrome patients
[18-21]. Patient self-assessment of symptoms is the gold
standard in the palliative care setting. However, patients
with a poor PS are unstable and suffer from various
symptoms; therefore, completing a self-assessment of
symptoms is difficult for these patients. In such situa-
tions, the use of a proxy assessment scale, such as the
STAS, by medical practitioners is useful because an
improvement in the STAS score was found to be the
most statistically significant prognostic factor in the
current study.
A meta-analysis of dose-fractionation RT trials found
no significant differences in complete or overall pain re-
lief between single- and multifraction palliative RT in
patients with bone metastasis [28]. Most cancer patients
destined for palliative RT have a very limited life span.
In such situations, finding a balance between the poten-
tial benefits of treatment and the risk of toxicity and
inconvenience for the patient is essential. The use of
protracted treatment regimens is not appropriate in
patients with a poor PS. In the current study, single-
fraction RT was administered in only two patients, and
14% of the patients were unable to complete the
planned palliative RT dose primarily due to general de-
terioration. Therefore, we suggest that single-fraction
palliative RT be considered in such cases and may be
worthwhile, especially in patients with poor prognostic
factors for survival.
Our study is associated with several limitations. First,
it is a retrospective study that introduces the possibility
of treatment selection bias. Moreover, it was a relatively
small case series conducted in a single institute, and
both the patient profiles and RT regimens were hetero-
geneous. Therefore, in the future, large prospective stud-
ies are required to investigate the actual benefits of
palliative RT, including the effects on survival and the
QoL, in patients with a poor PS.
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In summary, this is the first report that attempted to
assess the efficacy and tolerability of palliative RT in pa-
tients with a poor PS and to evaluate the relationship
between the palliative RT effect and the survival time
using the second item of the STAS. The use of palliative
RT in patients with a poor PS was found to be feasible,
and significant palliative effects were obtained, espe-
cially for pain, dyspnea and symptoms of increased
intracranial pressure. The palliative effect at one week
after the completion of RT was found to be strongly
correlated with prolongation of the survival time, which
may contribute to the assessment of the remaining sur-
vival time in metastatic/advanced cancer patients with
a poor PS. These results justify conducting further pro-
spective evaluations with detailed treatment protocols,
including those regarding the radiation dose and frac-
tionation, to clarify whether palliative RT can improve
the limited survival time and QoL in patients with a
poor PS.
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